BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year


6/8/2011 7:18:07 AM

NORTH KINGSTOWN, R.I., June 8, 2011 /PRNewswire/ -- Leading national medication monitoring company, Dominion Diagnostics, announces its support of Tufts Health Care Institute's (THCI) Program on Opioid Risk Management for a fourth consecutive year.

Dominion's support of THCI's Program on Opioid Risk Management began in 2007 as part of the company's commitment to promoting the safe and effective use of controlled opioid medications commonly prescribed for chronic pain patients. The Program aims to address the need to provide chronic pain patients with adequate opioid pharmacotherapy that enhances individual patient care while simultaneously reducing the risk of abuse and/or diversion.

"The mission of THCI's Opioid Risk Management Program is paramount to raising the standard of care for chronic pain patients and addressing the rapidly growing epidemic of prescription drug misuse," says Bob Garvey, Dominion's Chief Executive Officer. "It has become essential to engage such a diverse group of stakeholders in the development and implementation of programs that support prescription adherence, improve patient outcomes, and minimize risk through education, innovative clinical support, and evidence-based quality care."

Through a series of summit meetings each year, the THCI Opioid Risk Management Program provides a unique educational forum to encourage discussion among industry thought leaders. Summit meeting participants, including Dominion's representatives, review scientific and health industry findings relevant to opioid risk management, and discuss recommendations for future initiatives. The THCI Opioid Risk Management Program has distinguished itself nationally as a high value medium for its exchange of ideas, implementation of awareness goals, and resulting collaborations for research and publication.

Dominion will participate in a two-day summit this week that will focus on pharmacotherapy for prescription opioid addiction and the implications for pain management with other participants in the THCI Opioid Risk Management Program. For more information on the THCI Opioid Risk Management Program, please visit www.thci.org/opioid.

About Dominion Diagnostics

Dominion Diagnostics is a leading national medication monitoring company that offers comprehensive drug testing, scientifically accurate medication monitoring services and a full suite of clinical support solutions. Since 1997, Dominion has provided services to thousands of clients representing a diversity of medical specialties across the United States, including pain medicine, addiction medicine, behavioral health, primary care, psychiatry, and hospital systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information, please visit www.dominiondiagnostics.com.

For Media Inquiries, contact:
Julie K. Lenahan, MBA, Director of Marketing
Tel: (401) 667-0876, E-Mail: jlenahan@dominiondiagnostics.com

SOURCE Dominion Diagnostics, LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES